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Among the few Epstein-Barr virus (EBV) genes expressed during latency are the Epstein-Barr nuclear
antigens (EBNAs), at least one of which contributes to the ability of the virus to transform B lymphocytes. We
have analyzed a promoter located in the BamHI-C fragment of EBV which is responsible for the expression of
EBNA-1 in some cell lines. Deletion analysis of a 1.4-kb region 5' of the RNA start site has identified a 700-bp
fragment that is required for optimal promoter activity in latently infected B lymphocytes, as shown by
promoter constructs linked to the chloramphenicol acetyltransferase reporter gene. This fragment is also able
to enhance activity, in an orientation-independent manner, of the simian virus 40 early promoter linked to the
chloramphenicol acetyltransferase gene. The enhancer element has some constitutive activity in EBV-negative
lymphoid cells, which is increased in the presence of the EBNA-2 gene product. Further deletions have shown
that the EBNA-2-responsive region requires a 98-bp region that contains a degenerate octamer-binding motif.
In epithelial cells there was no enhancer activity regardless of the presence of EBNA-2. These results
demonstrate that BamHI-C promoter activity may be dependent not on an enhancer contained in the ori-P, as
was previously assumed, but rather on EBNA-2 transactivation of this more proximal enhancer located in the
upstream region of the BamHI C promoter itself.
The establishment and control of latency are principal
features of infection with the Epstein-Barr virus (EBV).
Latency and B-lymphocyte immortalization are biologically
intertwined, in that most if not all of the identified latent
EBV gene products are expressed in immortalized and
transformed cells. Expression of at least a subset of the
latent genes is required for the transformed state, but not all
of the viral and cellular genes needed for transformation
have been identified.
Maintenance of the EBV episomal genomic form, which is
the basis for viral latency (29), depends on the trans-acting
functions of a single EBV protein, EBNA-1 (35). The
EBNA-1 protein is synthesized early in the viral cycle, but
its appearance is preceded by the appearance of another
nuclear protein, EBNA-2 (26, 37), which has been implicated
in cell immortalization and transformation (7, 8, 17, 34, 41).
Details of the function of this nuclear antigen are largely
unknown, although it induces an increase in the expression
of a B-cell activation antigen, CD-23 (48), as well as an
increase in the level of RNA of the c-fgr proto-oncogene
(22). EBNA-2 also transactivates the promoter for the latent
membrane protein 1 (LMP-1), another latently expressed
viral gene product (1, 49). EBNA-2 alone is unable to
transform cells, but it may function to transactivate viral and
cellular promoters which in turn are responsible for the
expression of gene products necessary for transformation.
The messages encoding the EBNAs can arise from two
different promoters located near the origin of plasmid repli-
cation (ori-P), with some transcripts originating from a
promoter in the BamHI W region (38, 42) and others
originating from a promoter in BamHI-C (5). Promoter usage
for expression of these nuclear proteins may vary or shift in
different cell lines and differentiation states (50), but it
appears that BamHI-W promoter activity precedes BamHI-
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C promoter activity in latent infection and that gene products
transcribed from the BamHI W promoter may be required to
transactivate the BamHI C promoter (51).
We focus here on an analysis of the BamHI C promoter
because of its central role in the expression of the EBNA-1
protein as well as the other EBNAs. We show that the
EBNA-2 gene product increases expression of this promoter
and that this increase is due to the activation of a tissue-
specific enhancer located in the region 5' of the RNA start site.
MATERIALS AND METHODS
Cell lines. Raji (32) is a latently infected EBV-positive
Burkitt's lymphoma B-cell line, Louckes (47) is an EBV-
negative Burkitt's lymphoma B-cell line, Jurkat is an EBV-
negative T-cell line, and HEp-2 is an EBV-negative human
epithelial line. Other lines used include the human cervical
carcinoma line HeLa (which contains sequences from hu-
man papillomavirus type 18), the EBV-positive lymphoid
line P3HR-1 (34), the latently infected EBV-positive lym-
phoid line IB4 (21), which was derived by infection ofhuman
cord blood lymphocytes, and NPC-KT, an EBV-positive
epithelial line made by the fusion of an adenoidal carcinoma
line with a nasopharyngeal carcinoma line (46). All cells
were maintained at 37°C in a 5% CO2 environment. Lym-
phoid cells were grown in RPMI medium supplemented with
10% fetal calf serum, and epithelial lines were grown in
minimal essential medium with 10% fetal calf serum.
DNA transfections. Plasmid DNA was amplified in Esche-
richia coli and purified over two sequential cesium chloride
gradients. For each sample, 10 ,ug of plasmid DNA was
electroporated (27) into 107 cells at 1,500 V, using the
University of Wisconsin Zapper electroporation unit. Cells
were then suspended in 5 ml of RPMI 1640 medium supple-
mented with 10% fetal calf serum and incubated for 48 h at
37°C in 5% CO2.
Chloramphenicol acetyltransferase (CAT) assays. Extracts
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were prepared by washing cell pellets twice in phosphate-
buffered saline solution, suspending them in 200 ,ul of 0.25 M
Tris-Cl (pH 7.5), and freeze-thawing them four times. Reac-
tions were carried out as described previously (16) by
incubating each sample with acetyl coenzyme A and [14C]
chloramphenicol at 37°C for 2 h. Acetylated reaction prod-
ucts were separated by thin-layer chromatography, visual-
ized by autoradiography, and quantitated by scintillation
counting. Percent acetylation is calculated as the ratio of
counts per minute in the acetylated reaction products to
counts per minute in the entire sample.
Recombinant plasmids. A 1.4-kb Sau3A restriction frag-
ment containing the BamHI C RNA start site was cloned
into the BgllI site of the promoterless CAT expression
vector pCAT3M (24) as previously described (18). Con-
structs containing deletions of this fragment and constructs
to evaluate possible enhancer function were also made and
are described later. The pA1OCAT vector contains the CAT
gene under the control of the simian virus 40 early promoter
but lacks the simian virus 40 enhancer sequences (25). An
EBNA-2-expressing construct, CMV-EBNA-2, was made
by inserting a 2.1-kb MluI-AhaIII restriction fragment con-
taining the EBNA-2b coding region from the AG876 virus
into the pGem derivative pHD101-3 (9), where EBNA-2
expression is driven by the cytomegalovirus (CMV) imme-
diate-early promoter.
RNA analysis. An internally labeled single-stranded DNA
probe complementary to plasmid pC-CAT was made by
cloning a fragment from pC-CAT containing the intact pro-
moter region plus the CAT gene into the M13 phagemid
pBlueScribe (Stratagene). Single-stranded template DNA
was prepared by using M13KO7 helper phage, and a 20-base
primer that hybridized from 234 to 254 bases downstream of
the RNA start site was annealed to it. The primer was
extended and labeled with the Klenow enzyme and [32p]
dCTP. After digestion with SmaI, the strands were sepa-
rated on a denaturing polyacrylamide-urea gel. The appro-
priate-size band was detected by autoradiography and elec-
troeluted from the gel slice.
Cytoplasmic RNA from Jurkat cells was prepared 24 h
after transfection (2, 13), and then 50 ,ug was hybridized
overnight at 30°C to 105 cpm of the 32P-labeled probe. After
digestion with S1 nuclease, samples were electrophoresed
on a denaturing polyacrylamide-urea gel. The protected
fragment was visualized by autoradiography.
RESULTS
Constitutive activity of the Bam HI C promoter in different
cell types. A series of nested 5' deletions of the pC-CAT
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FIG. 1. Schematic representation of deletion constructs of the
BamHI C promoter region. (A) Nested deletions of the parent
promoter construct, a Sau3A fragment (EBV BamHI-C coordinates
5917 to 7343) extending from -1400 to +3 relative to the RNA start
site of the BamHI C promoter. Deletions were made by digestion
with the restriction enzymes shown and linked to the CAT gene in
the promoterless vector, pCAT3M. (B) Structures of Cd6787,
Cd6878, and Cd6976, which were made to localize the EBNA-2-
responsive region. The pC-CAT parent promoter construct was first
digested with KpnI and SmaI and then digested with exonuclease III
for various times, using the Erase-a-Base system (Promega). The
sequences of transformants were verified by dideoxy sequencing
(39). Constructs were named according to the EBV BamHI C
coordinate for the 3' end of each deletion.
parent construct (18) was made by restriction enzyme diges-
tion (Fig. 1A). Each of these deletions was transfected by
electroporation into different cell lines. The BamHI C pro-
moter is constitutively active in the EBV-negative lymphoid
cell lines Louckes and Jurkat, while the promoter remains
inactive in the epithelial line HEp-2 (Table 1). In the lym-
phoid cell lines, constitutive promoter activity drops dramat-
ically when sequences 5' of the Sacl site are deleted. In the
latently EBV-infected Raji cells, BamHI-C promoter activity
is up to 60-fold higher than in the uninfected lymphoid cells,
suggesting that an EBV latent gene product is required for
maximal promoter expression.
EBNA-2 induces an increase in expression of the BamHI C
promoter. We next examined the effect of the EBV latent
gene product EBNA-2 on expression from the BamHI C
promoter in the EBV-negative cell line Louckes. The pC-
CAT deletion constructs were cotransfected either with
CMV-EBNA-2 (Fig. 2, lanes 4, 6, 8, 10, and 12), which
TABLE 1. Effects of 5' deletions on BamHI-C promoter activity
Promoter activity
Cell line Cell type EBV
pC-CAT pC-dKpn pC-dSma pC-dSac pC-dMst
Louckes B lymphoid - 2.7a 4.3 5.3 1.0 1.0
(0.8-7.2) (1.6-10) (2.7-12.6) (0.3-2) (0.5-1.5)
Jurkat Tlymphoid - 7.6 5.6 13.8 1.7 0.9
(1.0-20) (0.9-2.3) (1.4-21) (1.3-2.6) (0.7-1.2)
Raji B lymphoid + 175.4 141.0 117.0 3.1 0.5
(54-357) (41-345) (83-154) (2.5-3.8) (0.4-0.6)
HEp-2 Epithelial - 0.7 0.2 0.7 0.1 0.1
(0.1-1.0) (0.1-0.4) (0.5-1.7) (0.0-0.4) (0.05-0.2)
a Expressed as the average fold increase in CAT activity over the value for the negative control plasmid, pCAT3M. CAT activity is measured by percent
acetylation. Ranges for each experiment are shown in parentheses.
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FIG. 2. Effect of EBNA-2 on CAT activity driven by the BamHI C promoter. pC-CAT deletion constructs were transfected into Louckes,
an EBV-negative B-lymphocyte line, and assayed for CAT activity. Lanes 1, positive control plasmid, RSVCAT; 2, negative control plasmid,
pCAT3M vector alone; 3, pC-CAT; 4, pC-CAT plus CMV-EBNA-2; 5, 7, 9, and 11, pC-dKpn, pC-dSma, pC-dSac, and pC-dMst in the
absence of CMV-EBNA-2; 6, 8, 10, and 12, pC-dKpn, pC-dSma, pC-dSac, and pC-dMst in the presence of CMV-EBNA-2. Numbers
represent the fold increase in the percent acetylation over the value for the negative control plasmid, pCAT3M.
expresses EBNA-2b under the control of the CMV immedi-
ate-early promoter, or with the pHD101-3 vector alone
(lanes 3, 5, 7, 9, and 11). The presence of the EBNA-2 gene
product resulted in increases, some striking, in the level of
CAT expression for those constructs containing sequences
5' of the Sacl restriction site (lanes 4, 6, and 8). Constructs
containing the two smallest deletions, pC-dSac and pC-dMst
(lanes 10 and 12), were unresponsive to EBNA-2. This same
pattern of transactivation was observed in Jurkat cells as
well as in the EBV-infected cell line P3HR-1, in which the
coding region for EBNA-2 is deleted (data not shown) (20,
34). No promoter activity was observed in the EBV-negative
epithelial cell lines HEp-2 and HeLa or in the EBV-positive
epithelial cell line NPC-KT, in the presence or absence of
EBNA-2 (data not shown). These results indicate that the
EBNA-2 gene product is needed for maximal expression
from the BamHI C promoter in lymphoid cells.
EBNA-2 transactivates an enhancer contained in the region
5' of the BamHI C promoter. The pattern of promoter
expression that emerged during the deletion studies indi-
cated that the region 5' of the Sacl site might contain an
enhancer. A 700-bp SmaI-MstII fragment containing the
putative enhancer was therefore cloned in both orientations
(C71 and C72) downstream of the CAT gene into the
pA1OCAT vector (Fig. 3). pC71 and pC72 were transfected
by electroporation into Raji cells, in which CAT expression
of the constructs containing inserts in both orientations was
enhanced over the background level (Table 2).
When pC71 and pC72 were tested in the EBV-negative cell
line Louckes, a low level of promoter activity was observed,
which was increased when the EBNA-2b-expressing plasmid
(CMV-EBNA-2) was cotransfected. Likewise, in another
EBV-negative lymphoid line, Jurkat, there was an increase






cotransfected with CMV-EBNA-2. CAT activities for all
three lymphoid cell lines are summarized in Table 2. These
results clearly demonstrate that the 700-bp Sma-Mst frag-
ment contains an enhancer element that is transactivated by
EBNA-2.
Enhancer activity is tissue specific. The enhancer element is
most active in lymphocytes when EBNA-2 is provided in
trans. The enhancer-containing constructs were also tested
in several epithelial cell lines. In the EBV-negative cell lines
HEp-2 and HeLa, no enhancer activity was observed in the
presence or absence of cotransfected EBNA-2 (Table 2).
The EBV-positive epithelial line NPC-KT was also tested,
and again no activity was observed (data not shown). These
results indicate that maximal expression from the BamHI C
promoter appears to require lymphoid cell factors in addition
to the EBNA-2 gene product.
RNA analysis. To confirm that the RNA start site for the
BamHI C promoter does not change in the presence of the
EBNA-2 transactivator, S1 nuclease analysis was per-
formed. pC-CATdKpn (5 ,ug) was transfected into the EBV-
negative lymphoid cell line Jurkat with 5 ,ug of either
pHD101-3 (Fig. 4, lane 1) or CMV-EBNA-2 (lane 2). Cyto-
plasmic RNA was harvested 24 h posttransfection and
hybridized to a 32P-labeled single-stranded DNA probe.
After digestion with Si nuclease, a protected DNA fragment
of 254 bp was expected, according to the previously deter-
mined RNA start site for the BamHI C promoter (5, 19, 45).
Our results demonstrate that in the presence of the EBNA-2
transactivator, the RNA start site remains unchanged and
the level of CAT RNA is increased.
EBNA-2 responsiveness requires a 98-bp region upstream of
the BamHI C promoter RNA start site. Exonuclease III
deletions of the pC-CAT parent promoter construct were
made as shown in Fig. 1B and transfected into the EBV-
I I Soac MstAI
I)|CAT p pC-CAT
Smal C71 MstII
700 bp pA OCAT
M3tll C72 SmolI
FIG. 3. Schematic representation of the plasmid construct used to test for the presence of an enhancer. A 700-bp SmaI-MstII fragment
containing the putative enhancer was cloned in both orientations (C71 and C72) into the pA1OCAT vector, in which the CAT gene is under
the control of the simian virus 40 (SV40) early promoter.
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TABLE 2. EBNA-2 transactivation of the BamHI C enhancer
Fold enhancementa
Construct EBNA-2 Lymphoid cellsb Epithelial cells
Raji Louckes Jurkat HeLa HEp-2
pC71 - 4.7 2.8 1.1 2.6
(2.4-8) (1.3-4.5) (0.8-1.6) (1.0-2.6)
+ 5.6 24.7 12.6 1.9 2.2
(3.3-9.8) (14.6-45) (7.2-19) (0.9-3.6) (1.9-2.6)
pC72 - 11.8 2.1 1.1 1.0
(3.0-19) (0.6-4.6) (1.0-1.2) (0.5-1.3)
+ 14.1 45.6 6.1 1.0 2.6
(7.9-18) (23-68) (4.5-7.0) (1.0-1.2) 1.4-3.6)
a Expressed as the percent acetylation of the pC71- and pC72-transfected samples relative to the percent acetylation in cells transfected with the pA1OCAT
vector alone. Ranges for each condition are shown in parentheses. Plasmid constructs are shown in Fig. 3.
b Raji cells constitutively express EBNA-2. In Jurkat and Louckes cells, plasmid CMV-EBNA-2 is cotransfected.
negative cell line Louckes. EBNA-2 transactivation was
maintained through the first two deletions (Fig. 5, lanes 2 to
5) but was eliminated altogether with the third deletion (lanes
6 and 7). These results demonstrate that this 98-bp fragment,
extending from BamHI-C nucleotides 6878 to 6976, is re-
quired for EBNA-2 responsiveness.
DISCUSSION
Identifying the mechanisms of regulation of EBV latent
promoters is essential to an understanding of the establish-
ment and control of latent infection as well as its contribu-
tion to lymphocyte immortalization. We have shown here
that maximum expression of the BamHI C promoter, one of
the promoters active during latency, is lymphoid specific and
requires transactivation of an enhancer by the EBV latent
gene product, EBNA-2.
In established latent EBV infection, the BamHI C pro-
moter is the primary promoter used for EBNA messages in
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of latent infection, messages encoding the EBNAs arise
primarily from a promoter within the BamHI W fragment,
which is present in multiple copies. BamHI-C promoter
activity is not observable until 3 days after infection (51),
implying that it requires viral or cellular factors for its
activation that are not immediately available upon infection.
It has been suggested by Sugden and Warren (45) that
EBNA-1, which can be transcribed from BamHI-W in some
cell lines, activates the BamHI C promoter by transactivat-
ing the enhancer in the ori-P. However, the promoter
constructs used in those experiments did not contain the
more proximal enhancer element (primarily EBNA-2 re-
sponsive) that we have now identified. The promoter con-
structs used in our experiments, on the other hand, did not
contain the more distal EBNA-1-responsive ori-P enhancer.
Given that the EBNA-2-responsive element that we have
identified is located much closer to the RNA start site for the
BamHI C promoter, it seems likely that this is the dominant
enhancer element used to drive expression from this pro-
moter. However, the two enhancers may work together to
regulate latent gene expression as well as replication.
At this point, it seems likely that EBNA-2 is initially
transcribed from the BamHI W promoter (51) and then
proceeds to transactivate the BamHI C promoter. Such
transactivation could be mediated directly by the binding of
1 2 3 4 5 6 7
230o'
1 2
FIG. 4. Si nuclease protection analysis: effect of EBNA-2 on
transcription from the BamHI C promoter. Shown on an autoradio-
gram of Si nuclease-protected DNA analyzed on a denaturing
polyacrylamide gel. Jurkat cells were transfected with pC-CATdkpn
and either pHD101-3 (lane 1) or CMV-EBNA-2 (lane 2). Cytoplas-
mic RNA was prepared from the transfected cells and hybridized to
a single-stranded DNA probe. Numbers (in nucleotides) represent
DNA standard molecular size markers.
DCAT3M Ld6787 J Ld687B J Ld6976I
CMV EDNA2
PHD 10 -3-
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FIG. 5. Localization of the EBNA-2-responsive region. Exonu-
clease III deletions of pC-CAT were transfected into Louckes cells,
in the presence and absence of cotransfected CMV-EBNA-2, and
assayed for CAT activity. Numbers represent the fold increase in
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FIG. 6. Regions of homology between the LMP and C promot-
ers. (A) 12-of-16-bp match; (B) 9-of-10-bp match, containing a
degenerate octamer-binding sequence, located within the 98-bp
EBNA-2-responsive region. Numbers reflect the distance from the
RNA start site for either promoter. (C) Consensus binding sequence
for the Oct-1 and Oct-2 transcription factors (11, 12, 31).
the EBNA-2 protein to a sequence in the upstream region,
although EBNA-2 has never been demonstrated to bind to a
specific DNA sequence. Another possibility is that EBNA-2
and other viral gene products may contribute to an alteration
in the differentiation state of the infected cell (7), resulting in
the expression of cellular factors that may in turn activate
the BamHI C promoter. This explanation seems more feasi-
ble given the evidence that EBNA-2 induces the expression
of vimentin (4) and the B-cell activation antigens CD-23 and
CD-21 (6, 48, 49), as well as inducing an increase in the level
of RNA of the c-fgr proto-oncogene (22).
EBNA-2 also transactivates the promoter for LMP, an-
other EBV latent gene product (1, 49). Ghosh and Kieff (15)
have identified an upstream region in the LMP promoter
which, when deleted, results in a decrease in LMP promoter
activity. Sharing homology with sequences in this region of
the LMP promoter are two short sequences within the
BamHI C promoter (Fig. 6). The first homologous sequence
(-559 CCCCCAGATGCCCCCC -543) (Fig. 6A) appears
not to be needed for EBNA-2 responsiveness of the BamHI
C promoter. However, deletion of 98 bp (Fig. 5, lanes 6 and
7) containing the second homologous sequence (-435
ACATGCACCC -425) (Fig. 6B) results in a complete in-
ability of EBNA-2 to transactivate the promoter. This 98 bp
is therefore required, but may not be sufficient, for EBNA-2
responsiveness.
The -435 to -425 sequence (relative to the RNA start site
for the BamHI C promoter) within this 98 bp contains a
five-of-eight-base match with the consensus binding site for
the Oct-1 and Oct-2 transcription factors (Fig. 6C) (11, 12,
31). This sequence could possibly act as a degenerate
octamer-binding motif. These motifs can mediate activation
of certain cellular and viral promoters and enhancers by a
ubiquitous cellular octamer-binding protein (3, 40, 44). Since
EBNA-2 can transactivate the BamHI C promoter only in
lymphoid cells, one possible mechanism of action for
EBNA-2 could be an interaction with a lymphoid-specific
octamer-binding protein (43), which may in turn activate the
BamHI C promoter through binding to this degenerate
octamer motif. This scenario could be analogous to the
mechanism by which VP16 activates the immediate-early
promoters of herpes simplex virus (14, 23, 30).
Although the BamHI C promoter appears to be the pri-
mary promoter used to activate EBNA expression in latently
infected B-cell lines, at this point it is not known whether the
same promoter is used to drive EBNA expression in epithe-
lial cells. EBV infection of epithelial cells is of particular
interest, since infection of nasopharyngeal epithelial cells is
strongly associated with the development of nasopharyngeal
carcinoma (10, 28, 33). Our data suggest that it is unlikely
that the BamHI C promoter is the primary promoter used to
drive EBNA expression in epithelial cells, since we were
unable to detect constitutive activity of the promoter in
epithelial cells, nor could we detect transactivation by
EBNA-2 in this cell type. It is therefore likely that EBNA
expression is differentially regulated in different cell types.
Moreover, since the BamHI W promoter, which can be used
alternatively for EBNA-1 expression, is also inactive in
epithelial cells (19, 36), there is a possibility that EBNA-1
mRNA arises from yet a third promoter or start site in
epithelial cells.
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